JP2021522280A5 - - Google Patents
Info
- Publication number
- JP2021522280A5 JP2021522280A5 JP2020560361A JP2020560361A JP2021522280A5 JP 2021522280 A5 JP2021522280 A5 JP 2021522280A5 JP 2020560361 A JP2020560361 A JP 2020560361A JP 2020560361 A JP2020560361 A JP 2020560361A JP 2021522280 A5 JP2021522280 A5 JP 2021522280A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- heterocycloalkyl
- cycloalkyl
- heteroaryl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024078186A JP2024112864A (ja) | 2018-04-30 | 2024-05-13 | Ｃｄ７３阻害剤 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862664841P | 2018-04-30 | 2018-04-30 | |
| US62/664,841 | 2018-04-30 | ||
| US201862737647P | 2018-09-27 | 2018-09-27 | |
| US62/737,647 | 2018-09-27 | ||
| US201862757714P | 2018-11-08 | 2018-11-08 | |
| US62/757,714 | 2018-11-08 | ||
| US201862777697P | 2018-12-10 | 2018-12-10 | |
| US62/777,697 | 2018-12-10 | ||
| US201962810790P | 2019-02-26 | 2019-02-26 | |
| US62/810,790 | 2019-02-26 | ||
| PCT/US2019/030068 WO2019213174A1 (en) | 2018-04-30 | 2019-04-30 | Cd73 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024078186A Division JP2024112864A (ja) | 2018-04-30 | 2024-05-13 | Ｃｄ７３阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021522280A JP2021522280A (ja) | 2021-08-30 |
| JP2021522280A5 true JP2021522280A5 (enExample) | 2022-04-26 |
| JP7489323B2 JP7489323B2 (ja) | 2024-05-23 |
Family
ID=68386646
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560361A Active JP7489323B2 (ja) | 2018-04-30 | 2019-04-30 | Ｃｄ７３阻害剤 |
| JP2024078186A Pending JP2024112864A (ja) | 2018-04-30 | 2024-05-13 | Ｃｄ７３阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024078186A Pending JP2024112864A (ja) | 2018-04-30 | 2024-05-13 | Ｃｄ７３阻害剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US11325938B2 (enExample) |
| EP (2) | EP4674481A3 (enExample) |
| JP (2) | JP7489323B2 (enExample) |
| KR (1) | KR20210018255A (enExample) |
| CN (2) | CN120699076A (enExample) |
| AU (1) | AU2019261976B2 (enExample) |
| BR (1) | BR112020022068A2 (enExample) |
| CA (1) | CA3098493A1 (enExample) |
| IL (1) | IL304348B2 (enExample) |
| MX (2) | MX2020011542A (enExample) |
| SG (1) | SG11202010790XA (enExample) |
| TW (1) | TW202014182A (enExample) |
| WO (1) | WO2019213174A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11129841B2 (en) | 2017-05-10 | 2021-09-28 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| US11377469B2 (en) * | 2017-11-03 | 2022-07-05 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| CA3098493A1 (en) | 2018-04-30 | 2019-11-07 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| TW202017569A (zh) * | 2018-05-31 | 2020-05-16 | 美商佩樂敦治療公司 | 用於抑制cd73之組合物及方法 |
| KR102902754B1 (ko) * | 2018-06-21 | 2025-12-19 | 안텐진 테라퓨틱스 리미티드 | 엑토뉴클레오티다제 저해제 및 이의 사용 방법 |
| JP2022522534A (ja) | 2019-04-02 | 2022-04-19 | アリゴス セラピューティクス インコーポレイテッド | Ｐｒｍｔ５を標的にする化合物 |
| US12544391B2 (en) | 2019-07-16 | 2026-02-10 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| CN116854758A (zh) | 2019-10-30 | 2023-10-10 | 欧瑞克制药公司 | Cd73抑制剂 |
| CN116546990B (zh) * | 2020-11-25 | 2026-05-26 | 润佳（苏州）医药科技有限公司 | Cd73抑制剂及其药学应用 |
| TW202308657A (zh) | 2021-05-11 | 2023-03-01 | 大陸商四川海思科製藥有限公司 | 小分子cd73拮抗劑及其用途 |
| US20240140980A1 (en) * | 2022-10-03 | 2024-05-02 | Teon Therapeutics, Inc. | Heterocyclic inhibitors of cd73 for treatment of disease |
| US20240140979A1 (en) * | 2022-10-03 | 2024-05-02 | Teon Therapeutics, Inc. | Heterocyclic inhibitors of cd73 for treatment of disease |
| CN116217644B (zh) * | 2023-04-24 | 2023-08-08 | 南京颐媛生物医学研究院有限公司 | 抗冠状病毒核糖核苷类化合物及其制备方法和应用 |
| WO2025162964A1 (en) | 2024-01-30 | 2025-08-07 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of endometriosis |
| WO2025233264A1 (en) | 2024-05-07 | 2025-11-13 | Innate Pharma | Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers |
| US20260159615A1 (en) | 2024-12-09 | 2026-06-11 | Chevron Phillips Chemical Company Lp | Metallocenes containing alkenyloxyphenyl groups producing high molecular weight polyethylene |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0477454A1 (en) * | 1990-09-28 | 1992-04-01 | Merrell Dow Pharmaceuticals Inc. | Novel phosphonate derivatives of certain nucleosides |
| JP2005502580A (ja) | 2000-12-15 | 2005-01-27 | フアーマセツト・リミテツド | フラビウィルス感染治療用抗ウィルス薬 |
| US20040229839A1 (en) * | 2003-05-14 | 2004-11-18 | Biocryst Pharmaceuticals, Inc. | Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| WO2005020885A2 (en) | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
| WO2007139946A2 (en) | 2006-05-25 | 2007-12-06 | University Of Tennessee Research Foundation | Gpcr ligands identified by computational modeling |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| WO2009127230A1 (en) | 2008-04-16 | 2009-10-22 | Curevac Gmbh | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION |
| US20090274686A1 (en) * | 2008-05-02 | 2009-11-05 | Yat Sun Or | Nucleoside phosphonate derivatives |
| EP3134411B1 (en) | 2014-04-25 | 2021-06-30 | Boehringer Ingelheim International GmbH | Purine derivatives as cd73 inhibitors for the treatment of cancer |
| CN104530166B (zh) | 2014-12-04 | 2016-08-24 | 陕西汉江药业集团股份有限公司 | 选择性还原4,6-共轭双烯-3-酮甾体化合物的方法 |
| WO2017098421A1 (en) * | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
| LT3399984T (lt) | 2016-01-08 | 2023-11-10 | Arcus Biosciences, Inc. | 5'-nukleotidazės, ekto moduliatoriai ir jų panaudojimas |
| CN110234656B (zh) * | 2016-09-09 | 2023-02-28 | 卡利泰拉生物科技公司 | 外核苷酸酶抑制剂及其使用方法 |
| WO2018067424A1 (en) * | 2016-10-03 | 2018-04-12 | Arcus Biosciences, Inc. | Inhibitors of adenosine 5'-nucleotidase |
| CN110022881B (zh) | 2016-11-18 | 2023-05-02 | 艾库斯生物科学有限公司 | Cd73介导的免疫抑制的抑制剂 |
| KR102638592B1 (ko) | 2016-12-22 | 2024-02-19 | 안텐진 테라퓨틱스 리미티드 | 엑토뉴클레오티다제 억제제 및 이의 용도 |
| WO2018183635A1 (en) * | 2017-03-31 | 2018-10-04 | Peloton Therapeutics, Inc. | Cd73 inhibitors and uses thereof |
| WO2018208727A1 (en) | 2017-05-08 | 2018-11-15 | Eternity Bioscience Inc. | Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof |
| US11129841B2 (en) | 2017-05-10 | 2021-09-28 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| US11377469B2 (en) | 2017-11-03 | 2022-07-05 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| CA3098493A1 (en) | 2018-04-30 | 2019-11-07 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| TW202017569A (zh) | 2018-05-31 | 2020-05-16 | 美商佩樂敦治療公司 | 用於抑制cd73之組合物及方法 |
| KR102902754B1 (ko) | 2018-06-21 | 2025-12-19 | 안텐진 테라퓨틱스 리미티드 | 엑토뉴클레오티다제 저해제 및 이의 사용 방법 |
| ES3053198T3 (en) | 2018-08-27 | 2026-01-20 | Arcus Biosciences Inc | Cd73 inhibitors |
| CA3143496A1 (en) | 2019-06-20 | 2020-12-24 | Antengene Therapeutics Limited | Ectonucleotidase inhibitors and methods of use thereof |
| US12544391B2 (en) | 2019-07-16 | 2026-02-10 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| CN116854758A (zh) | 2019-10-30 | 2023-10-10 | 欧瑞克制药公司 | Cd73抑制剂 |
-
2019
- 2019-04-30 CA CA3098493A patent/CA3098493A1/en active Pending
- 2019-04-30 SG SG11202010790XA patent/SG11202010790XA/en unknown
- 2019-04-30 CN CN202510454173.9A patent/CN120699076A/zh active Pending
- 2019-04-30 CN CN201980044455.4A patent/CN112423764A/zh active Pending
- 2019-04-30 IL IL304348A patent/IL304348B2/en unknown
- 2019-04-30 BR BR112020022068-0A patent/BR112020022068A2/pt not_active Application Discontinuation
- 2019-04-30 TW TW108115143A patent/TW202014182A/zh unknown
- 2019-04-30 EP EP25202200.9A patent/EP4674481A3/en not_active Withdrawn
- 2019-04-30 EP EP19796584.1A patent/EP3787635B1/en active Active
- 2019-04-30 AU AU2019261976A patent/AU2019261976B2/en active Active
- 2019-04-30 MX MX2020011542A patent/MX2020011542A/es unknown
- 2019-04-30 WO PCT/US2019/030068 patent/WO2019213174A1/en not_active Ceased
- 2019-04-30 JP JP2020560361A patent/JP7489323B2/ja active Active
- 2019-04-30 KR KR1020207034512A patent/KR20210018255A/ko not_active Ceased
-
2020
- 2020-10-23 US US17/078,567 patent/US11325938B2/en active Active
- 2020-10-29 MX MX2023002507A patent/MX2023002507A/es unknown
-
2022
- 2022-03-17 US US17/697,318 patent/US11807658B2/en active Active
-
2023
- 2023-09-28 US US18/476,763 patent/US20240124512A1/en not_active Abandoned
-
2024
- 2024-05-13 JP JP2024078186A patent/JP2024112864A/ja active Pending
-
2025
- 2025-06-11 US US19/234,635 patent/US20250368677A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024520481A5 (enExample) | ||
| JP2021527638A5 (enExample) | ||
| JP2012526728A5 (enExample) | ||
| JP2024100974A5 (enExample) | ||
| JP2017536395A5 (enExample) | ||
| JP2017512833A5 (enExample) | ||
| JP2021513534A5 (enExample) | ||
| JP2024541910A5 (enExample) | ||
| JP2024539946A5 (enExample) | ||
| JP2020530487A5 (enExample) | ||
| JP2020531422A5 (enExample) | ||
| JP2014511876A5 (enExample) | ||
| JP2018533593A5 (enExample) | ||
| JP2017523169A5 (enExample) | ||
| JP2021523200A5 (enExample) | ||
| JP2023553835A5 (enExample) | ||
| JP2020128426A5 (enExample) | ||
| JP2018529650A5 (enExample) | ||
| JP2015537008A5 (enExample) | ||
| JP2018537413A5 (ja) | 化合物、医薬的に許容される塩又はその立体異性体及び医薬組成物 | |
| RU2017121906A (ru) | Конъюгаты цистеамина и жирной кислоты и их применение в качестве активаторов аутофагии | |
| JP2017508816A5 (enExample) | ||
| JP2020535124A5 (enExample) | ||
| JP2016530259A5 (enExample) | ||
| JP2017524025A5 (enExample) |